These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8476215)

  • 21. [Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers].
    Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
    Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1607-15. PubMed ID: 2809385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients.
    Verma V; Sharma V; Shrivastava SK; Nadkarni JJ
    J Exp Clin Cancer Res; 2000 Sep; 19(3):367-74. PubMed ID: 11144531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of intraperitoneal administration of OK-432 with recombinant interleukin-2 to patients with peritonitis carcinomatosa of recurrent gynecological cancer and changes in ascitic lymphocyte subsets].
    Kanaoka Y; Umesaki N
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 May; 43(5):489-96. PubMed ID: 2056223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intra-tumoral injection therapy in patients with hepatocellular carcinoma].
    Watanabe S; Kagawa H; Shirai M; Nishioka M
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1635-41. PubMed ID: 3015038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-2-activated cord blood mononuclear cells.
    Derzic S; Slone V; Sender L
    Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [NK activities in cancer patients--their modification by an immunopotentiator].
    Sasanami T; Fujishima A; Moriya Y; Imai K; Yachi A
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2186-92. PubMed ID: 7184392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of in vitro LAK generation by OK-432.
    Yagita M; Grimm EA
    Cancer Immunol Immunother; 1986; 23(3):207-13. PubMed ID: 3491681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of lymphokine-activated killer cell development in young and old healthy humans.
    Provinciali M; Di Stefano G; Fabris N
    Nat Immun; 1995; 14(3):134-44. PubMed ID: 8832897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A basic study of combination cancer immunotherapy with OK-432 and rIL-2--induction of lymphokine-activated killer (LAK) precursor cells in murine spleen by intravenous administration of OK-432].
    Shimoda K; Saito T; Kobayashi M
    Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1566-73. PubMed ID: 3263451
    [No Abstract]   [Full Text] [Related]  

  • 31. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effective mechanisms of BRM, with special reference to induction of autologous tumor cell-killing (ATK) activity by OK-432].
    Hoshino T; Uchida A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1277-84. PubMed ID: 3488024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphofunctional characterization of lymphokine activated killer (LAK) cells in vitro.
    Nano R; Capelli E; Gerzeli G
    Boll Soc Ital Biol Sper; 1995; 71(7-8):181-7. PubMed ID: 8519494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
    Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
    Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients.
    Arinaga S; Akiyoshi T; Tsuji H
    Int J Immunopharmacol; 1988; 10(1):47-51. PubMed ID: 2966774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
    Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N
    J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery.
    West E; Morgan R; Scott K; Merrick A; Lubenko A; Pawson D; Selby P; Hatfield P; Prestwich R; Fraser S; Eves D; Anthoney A; Twelves C; Beirne D; Patel P; O'Donnell D; Watt S; Waller M; Dietz A; Robinson P; Melcher A
    J Immunother; 2009 Jan; 32(1):66-78. PubMed ID: 19307995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
    Komatsu F; Ishiguro K
    Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients.
    Provinciali M; Di Stefano G; Stronati S; Raffaeli W; Pari G; Fabris N
    Int J Immunopharmacol; 1996 Oct; 18(10):577-86. PubMed ID: 9080251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of exercise-induced augmentation of lymphokine activated killer (LAK) cell activity in the horse.
    Horohov DW; Keadle TL; Pourciau SS; Littlefield-Chabaud MA; Kamerling SG; Keowen ML; French DD; Melrose PA
    Vet Immunol Immunopathol; 1996 Oct; 53(3-4):221-33. PubMed ID: 8969043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.